Opioid-induced respiratory depression and monitoring patients diagnosed with obstructive sleep apnea

HIMSS Future Care posting:

Managing patients on the general care floor (GCF) who are either at risk or “diagnosed with obstructive sleep apnea (OSA), and those in particular who meet the requirements of the STOP-BANG criteria for OSA, can be quite challenging. The ECRI Institute, a federally-certified patient safety and research organization, has identified in its 2017 list of Top 10 Health Technology Hazards “Undetected Opioid-Induced Respiratory Depression” as Number 4 [1]. Opioids used for treatment of acute postoperative pain is rather commonplace, and patients at-risk for OSA, if left unattended, can experience anoxic brain injury or death.

Author: johnrzaleski_eqbr0v

John R. Zaleski, PhD, CAP, CPHIMS, is Chief Analytics Officer of Bernoulli, a leader in real-time connected healthcare. Dr. Zaleski brings 21 years of experience in researching and ushering to market devices and products to improve healthcare. He received his PhD from the University of Pennsylvania, with a dissertation that describes a novel approach for modeling and prediction of post-operative respiratory behavior in post-surgical cardiac patients. Dr. Zaleski has a particular expertise in designing, developing, and implementing clinical and non-clinical point-of-care applications for hospital enterprises. Dr. Zaleski is the named inventor or co-inventor on seven issued patents related to medical device interoperability. He is the author of numerous peer-reviewed articles on clinical use of medical device data, information technology and medical devices and wrote three seminal books on integrating medical device data into electronic health records and the use of medical device data for clinical decision making, including the #1 best seller of HIMSS 2015 on connected medical devices.

Leave a Reply

Your email address will not be published. Required fields are marked *